View Older Stories View More Recent Stories
-
Roth Capital Resumes Neogenomics (NEO) at Buy
-
Roth Capital Downgrades ContraFect Corp. (CFRX) to Neutral
-
Roth Expects Inline Q1 Results from Plug Power (PLUG); GenKey Growth Remains Focus
-
Roth Capital Downgrades Krispy Kreme (KKD) to Neutral
-
Roth Affirms Stemline Therapeutics (STML) at 'Buy'; Focus Now on June ASCO Presentation
-
Sophiris Bio (SPHS) Raising $5M Through ATM Offering
-
ROTH Capital Partners to Host Precious Metal Corporate Access Day in New York on May 18, 2016
-
Roth Capital Downgrades Diamondback Energy (FANG) to Neutral
-
Revolution Lighting Technologies Closes Previously Announced Acquisition of TNT Energy, LLC and $16.8 Million Underwritten Offering of Common Stock
-
Hannon Armstrong Management to Present at Deutsche Bank Clean Tech, Utilities and Power Conference; Cowen & Company Technology, Media & Telecom Conference; REITWeek 2016: NAREIT's Investor For
-
Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering
-
FuelCell's (FCEL) Carbon Capture Agreement with Exxon is 'Significant Positive'; Roth Affirms at 'Buy'
-
ROTH Capital Partners' Joe Reagor Interviewed by The Gold Report
-
Roth Capital Downgrades Cogentix Medical (CGNT) to Neutral
-
Roth Capital Upgrades LivePerson (LPSN) to Buy
-
Roth Capital Downgrades Synergy Resources Corporation (SYRG) to Neutral
-
Roth Affirms 'Neutral' Rating on SolarCity (SCTY); IRR on Equity Monetization Slightly Better than Expected
-
Roth Capital Downgrades Glu Mobile (GLUU) to Neutral
-
Global Water Resources, Inc. completes merger with GWR Global Water Resources Corp. and closes U.S. initial public offering
-
Neuralstem Prices Underwritten Public Offering of Securities
-
Revolution Lighting (RVLT) Prices 2.775M Common Stock Offering at $5.25/Share
-
Revolution Lighting Technologies Prices $14.6 Million Underwritten Offering of Common Stock
-
Neuralstem (CUR) to Offer Common Stock
-
Neuralstem Announces Proposed Public Offering of Securities
-
Biocept (BIOC) Prices 5M Common Stock, Warrants Offering at $1/Share
-
Biocept, Inc. Announces Pricing Of $5 Million Public Offering Of Common Stock And Warrants
-
ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report
-
Global Water Resources, Inc. announces pricing of initial public offering
-
Roth Affirms Ballard Power (BLDP) at 'Buy' Following Q1 Results; Cost Controls Firm, Order Book Growing
-
Ring Energy, Inc. Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
-
Roth Affirms Ligand Pharma (LGND) at 'Buy' Following FDA Acceptance of Lundbeck's CE-Carbamazepine NDA Resubmission
-
Mark E. Rose Joins LiquidSpace Board of Directors
-
Roth Keeps AmpliPhi (APHB) at 'Buy' as AB-SA01 Shows Early Progress in Chronic Rhinosinusitis
-
Orphan Drug Exclusivity for Spectrum's (SPPI) Evomela is Important Increment for Ligand (LGND) - Roth Capital
-
Roth Capital Starts ID Systems (IDSY) at Buy
-
Synergy's (SGYP) Plecanatide Seen as 'Rare Gem' at Roth Capital
-
Roth Boosts PT on Argos Therapeutics (ARGS) to $18; Focus Remains on ADAPT, IDMC Looks
-
Rimini Street Announces Preliminary Fiscal 2016 Q1 Financial Results
-
Gemphire Therapeutics (GEMP) Files $60M IPO
-
The PIPEs Report Sees Small-Cap Equity Financing Growth at the End of Q1 2016
-
Roth Capital Affirms Celldex (CLDX) at 'Buy'; Says Growing Varli Profile Continues to be Impressive
-
Streetinsider.com's Hot Lunchtime Reads :(CPXX) (CLBS) (TAST) (RLYP)
-
Roth Capital Affirm Celator Pharma (CPXX) at 'Buy'; Says FLT3-ITD Patients Have a New Enemy in Vyxeos
-
Roth Capital Reinstates XO Group (XOXO) at Buy
-
Roth Capital Starts Mitek Systems (MITK) at Buy
-
Roth Capital Starts Shopify (SHOP) at Buy
-
Roth Sees AmpliPhi's (APHB) Termination of Intrexon (XON) ECC at 'Smart Move'; Affirms at 'Buy'
-
Roth Capital Starts Five9, Inc (FIVN) at Buy
-
Roth Capital Starts Glaukos Corporation (GKOS) at Buy
-
Synta Pharma (SNTA), Madrigal Pharma Enter All-Stock Merger Agreement

